89Zr-LNCab103

N/A

Report date: 2025/09/15 11:01:12

Base Information

Drug Name89Zr-LNCab103
Drug Alias Name89Zr-LNCab103
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4] 
Mechanisms of ActionPositron-emission tomography enhancersAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast NeoplasmsCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAffiliated Hospital of Jiangnan University
China Registration ClassN/A

Develop Information

Active CompaniesAffiliated Hospital of Jiangnan University
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast NeoplasmsCarcinoma, Transitional Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A